Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVETIRACETAM IN SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Adjunctive therapy in the treatment of partial-onset seizures in adults and children ≥1 month,Adjunctive therapy in myoclonic seizures in adults and children ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy in primary generalized tonic-clonic seizures in adults and children ≥6 years with idiopathic generalized epilepsy
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
6-8 hours in adults; prolonged in elderly (10-11 h) and renal impairment (up to 25 h in ESRD)
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Levetiracetam is primarily eliminated renally; approximately 24% undergoes metabolism by hydrolysis of the acetamide group, not dependent on CYP450 enzymes.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
66% renal (unchanged), 27% as inactive metabolite (UCB L057) via renal; <1% fecal
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
<10% (negligible); not bound to albumin or alpha-1-acid glycoprotein
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.5-0.7 L/kg; approximates total body water, indicating extensive distribution into tissues and CNS
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IV: 100%; Oral: 100% (rapid and complete absorption)
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Cr Cl >80 m L/min: 500-1500 mg every 12h; Cr Cl 50-80: 500-1000 mg every 12h; Cr Cl 30-50: 250-750 mg every 12h; Cr Cl <30: 250-500 mg every 12h; ESRD: 500-1000 mg every 24h with 250-500 mg supplement post-dialysis.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): reduce maintenance dose by 50%.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
1 month to <6 months: 7 mg/kg/dose IV every 12h; 6 months to <4 years: 10 mg/kg/dose IV every 12h; 4 to <16 years: 10 mg/kg/dose IV every 12h up to 30 mg/kg/day. Maximum 3000 mg/day.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Initiate at 500 mg twice daily, titrate slowly due to age-related renal function decline; adjust dose per creatinine clearance.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA black box warnings.
None.
Behavioral and psychiatric symptoms: aggression, agitation, anger, anxiety, depression, mood swings, psychosis, suicidal ideation,Somnolence and fatigue,Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (e.g., decreased white blood cell counts),Hypersensitivity reactions including angioedema,Renal impairment requires dose adjustment
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to levetiracetam or any component of the formulation
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions. Levetiracetam can be taken with or without food. Avoid excessive alcohol consumption as it may increase CNS depression.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second and third trimesters may lead to fetal growth restriction and neurodevelopmental effects. The risk appears dose-dependent.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Infant exposure is estimated to be 1-2% of the maternal weight-adjusted dose. No adverse effects have been reported in breastfed infants, but caution is recommended.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy may decrease levetiracetam plasma concentrations by up to 40-60% due to increased clearance. Dose adjustment is often required: monitor serum trough levels and increase dose as needed to maintain therapeutic levels. Postpartum, monitor for potential dose reduction.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor for behavioral and psychiatric symptoms, especially in pediatric patients. Infusion rate should not exceed 5 mg/kg/min. Risk of suicidal thoughts and behavior. Caution in renal impairment; adjust dose based on creatinine clearance. Levetiracetam is not significantly protein-bound and has minimal drug interactions. May cause somnolence, dizziness, and coordination difficulties.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any new or worsening depression, agitation, hostility, or suicidal thoughts immediately.,Do not drive or operate heavy machinery until you know how levetiracetam affects you; it may cause dizziness or sleepiness.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double dose.,Do not stop taking levetiracetam abruptly; this can increase seizure frequency.,Inform all healthcare providers that you take levetiracetam, especially before surgery or emergency treatment.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Levetiracetam, an antiepileptic drug, may potentiate the sedative effects of pramipexole, a dopamine agonist used for Parkinson's disease and restless legs syndrome. This additive pharmacodynamic interaction results in increased central nervous system depression, leading to enhanced drowsiness, dizziness, and impaired psychomotor function. Clinically, patients may experience excessive sedation, reduced alertness, and an increased risk of falls or accidents, particularly during treatment initiation or dose adjustments."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
"Thiothixene, a typical antipsychotic, can lower the seizure threshold, increasing the risk of convulsions, particularly in patients with epilepsy. Levetiracetam, an anticonvulsant, may be less effective if seizure threshold is reduced, potentially leading to breakthrough seizures. Additionally, both drugs can cause CNS depression, leading to additive sedation, dizziness, and impaired cognitive function."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVETIRACETAM IN SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
LEVETIRACETAM IN SODIUM CHLORIDE is a Electrolyte that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVETIRACETAM IN SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVETIRACETAM IN SODIUM CHLORIDE is: 500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVETIRACETAM IN SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVETIRACETAM IN SODIUM CHLORIDE is classified as Category A/B. Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.